SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.
On November 14, 2023, at 10:55 a.m. EST, Trey Martin, Chief Executive Officer (CEO) and Kevin Herde, Chief Financial Officer (CFO), will participate in a fireside chat at the Stifel Healthcare Conference, 2023, being held at the Lotte New York Palace Hotel, in New York City, NY.
On November 16, 2023, at 2:00 p.m. GMT, Trey Martin, Chief Executive Officer (CEO) and Kevin Herde, Chief Financial Officer (CFO), will participate in a fireside chat at the Jefferies London Healthcare Conference, 2023, being held at the Waldorf Hilton, in London, England.
A live webcast of the presentations will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events. An archived version of the webcasts will also be available on the Maravai website following the completion of each event.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Contact Information:
Media Contact:
Sara Michelmore
MacDougall Advisors
+1 781-235-3060
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.42 |
Daily Change: | -0.78 -15.00 |
Daily Volume: | 4,056,473 |
Market Cap: | US$625.650M |
November 07, 2024 November 07, 2024 September 24, 2024 August 28, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB